Impact of depressive symptoms on outcomes of a workplace smoking-cessation program
DOI:
https://doi.org/10.20882/adicciones.198Keywords:
Nicotine dependence, smoking, tobacco, depression, treatment, workplaceAbstract
Introduction: Although smoking and depression have been related, little importance is given to the impact of depression on outcomes of smoking cessation interventions in the workplace. The aim of this study was to assess the influence of depressive symptoms and a history of depression on abstinence after a workplace smoking cessation intervention, and to explore the roles of gender, nicotine dependence and antidepressants. Methods: A retrospective study with employees of Barcelona City Council participating on a voluntary basis. The intervention consisted of a multicomponent approach combined with pharmacological treatment. Depressive symptoms were assessed with the Beck Depression Inventory (BDI), and history of depression was noted in the baseline assessment. Results: Higher scores in BDI were associated with lower rates of abstinence at 3, 6 and 12 months. BDI scores ≥ 13 were related to a 1.81x higher likelihood of relapse. This relationship was independent of the effect of dependence severity, of gender and of treatment with antidepressants. In contrast, a history of depression did not influence outcomes. Conclusions: New therapeutic strategies are needed to reduce the impact of employees’ depressive symptoms in workplace smoking cessation programmes.References
Encuesta Nacional de Salud 2006. Instituto Nacional de
Estadística. Disponible en: http://www.msc.es/estadEstudios/
estadisticas/encuestaNacional/encuesta2006.htm.
Moher M, Hey K, Lancaster T. Intervenciones en el lugar de
trabajo para el abandono del hábito de fumar (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, Número 2. Oxford: Update Software; 2006.
National Institute for Health and Clinical Experience. Workplace health promotion: how to help employees to stop smoking. London: National Institute for Health and Clinical Experience; 2007.
Kenney BA, Holahan CJ, North RJ, Holahan CK. Depressive
symptoms and cigarette smoking in American workers. Am J
Health Promot 2006; 20: 179-82.
Anda RF, Williamson DF, Escobedo LG, Mast EE, Giovino GA,
Remington PL. Depression and the dynamics of smoking. A
national perspective. JAMA 1990; 264: 1541-5.
Covey LS, Tam D. Depressive mood, the single-parent home, and adolescent cigarette smoking. Am J Public Health 1990; 80: 1330-3.
Wilhelm K, Wedgwood L, Niven H, Kay-Lambkin F. Smoking
cessation and depression: current knowledge and future
directions. Drug Alcohol Rev 2006; 25: 97-107.
Glassman AH, Stetner F, Walsh BT, Raciman PS, Fleiss JL, Cooper TB, et al. Heavy smokers, smoking cessation, and clonidine: Results of a double-blind, randomised trial. JAMA 1988; 259: 2863-6.
Glassman AH, Helzer JE, Covey LS, Cottler LB, Stetner F, Tipp JE, et al. Smoking, smoking cessation and major depression. JAMA 1990; 264: 1546-9.
Covey LS, Glassman AH, Stetner F, Becker J. Effect of history of alcoholism or major depression on smoking cessation. Am J Psychiatry 1993; 150: 1546-7.
Hall SM, Reus VI, Muñoz RF, Sees KL, Humfleet G, Hartz DT, et al. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry 1998; 55: 683-90.
Covey LS, Glassman AH, Stetner F. Depression and depressive symptoms in smoking cessation. Compr Psychiatry 1990; 31: 350-4.
Breslau N, Peterson EL, Schultz LR, Chilcoat HD, Andreski P. Major depression and stages of smoking. Arch Gen Psychiatry 1998; 55: 161-6.
Cox LS, Patten CA, Niaura RS, Decker AP, Rigotti N, Sachs DP, et al. Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression. J Gen Intern Med 2004; 19: 828-34.
Ginsberg JP, Klesges RC, Johnson KC, Eck LH, Meyers AW, Winders SA. The relationship between a history of depression and adherence to a multicomponent smoking-cessation program. Addict Behav 1997; 22: 783-7.
Hall S, Muñoz R, Reus V. Cognitive-behavioral intervention
increases abstinence rates for depressive-history smokers. J
Consult Clin Psychol 1994; 62: 141-6.
Hayford KE, Patten CA, Rummans TA, Schroeder DR, Offord KP, Croghan IT, et al. Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br J Psychiatry 1999; 174: 173-8.
Hitsman B, Borrelli B, McChargue DE, Spring B, Niaura R. History of depression and smoking cessation outcome: a meta-analysis. J Consult Clin Psychol 2003; 71: 657-63.
Kinnunen T, Doherty K, Militello FS, Garvey AJ. Depression and smoking cessation: characteristics of depressed smokers and effects on nicotine replacement. J Consult Clin Psychol 1996; 64: 791-8.
Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. In: Cochrane Database of Systematic Reviews, Issue 4. Oxford: Update Software; 2006.
Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical practice guideline. Rockville: U.S. Department of Health and Human Services, Public Health Service; 2008.
Conde V, Useros E. Adaptación castellana de la escala de
evaluación conductual para la depresión de Beck. Rev Psiquiatr
Psicol Med Eur Am Lat 1975; 12: 217-36.
Heatherton TF, Kozowski LT, Frecker RC, Fagerström KO. The
Fagerström test for nicotine dependence: a revision of the
Fagerström Tolerance Questionnaire. Brit J Addict 1991; 86:1119-27.
Cummings SR, Richard RJ. Optimum cutoff points for biochemical validation of smoking status. Am J Public Health 1988; 78, 574-5.
Hughes JR, Keely JP, Niara RS, Ossip-Klein DJ, Richmond RL,
Swan Ge. Measures of abstinence in clinical trials: issues and
recommendations. Nicotine Tob Res 2003; 5:13-25.
Michalak EE, Murria G, Wilkinson C, Dowrick C, Lasa L, Lehtinen V, et al. Estimating depression prevalence from the Beck Depression Inventory: is season of administration a moderator? Psychiatry Res 2004;129: 99-106.
Wetter DW, McClure JB, de Moor C, Cofta-Gunn L,Cummings S, Cinciripini PM, et al. Concomitant use of cigarettes and smokeless tobacco: prevalence, correlates, and predictors of tobacco cessation. Prev Med 2002; 34: 638-48.
Razavi D, Vandecasteele H, Primo C, Bodo M, Debrier F, Verbist H, et al. Maintaining abstinence from cigarette smoking:
effectiveness of group counselling and factors predicting
outcome. Eur J Cancer 1999; 35: 1238-47.
Lang T, Nicaud V, Slama K, Hirch A, Imbernon E, Goldberg M, et al. Smoking cessation at the workplace. Results of a randomised controlled intervention study. J Epidemiol Community Health 2000; 54: 349-54.
Smedslund G, Fisher KJ, Boles SM, Lichtenstein E. The effectiveness of workplace smoking cessation programmes: a meta-analysis of recent studies. Tob Control 2004;13:197-204.
Society for Research on Nicotine and Tobacco Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and cessation. Nicotine Tob Res 2002; 4, 149-59.
Brown RA, Kahler CW, Niaura R, Abrams DB, Sales SD, Ramsey SE, et al. Cognitive-behavioral treatment for depression in smoking cessation. J Consult Clin Psychol 2001; 69: 471-80.
Hass AL, Muñoz RF, Humfleet GL, Reus V, Hall SM. Influences of mood, depression history, and treatment modality on outcomes in smoking cessation. J Consult Clin Psychol 2004; 72: 563-70.
Brown RA, Niaura R, Lloyd-Richardson EE, Strong DR, Kahler
CW, Abrantes AM, et al. Bupropion and cognitive-behavioral
treatment for depression in smoking cessation. Nicotine Tob Res
; 9: 721-30.
